La Jolla Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LA JOLLA PHARMA, and when can generic versions of LA JOLLA PHARMA drugs launch?
LA JOLLA PHARMA has one approved drug.
There are eleven US patents protecting LA JOLLA PHARMA drugs.
There are forty-one patent family members on LA JOLLA PHARMA drugs in twenty-three countries.
Summary for La Jolla Pharma
| International Patents: | 41 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for La Jolla Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| La Jolla Pharma | GIAPREZA | angiotensin ii acetate | SOLUTION;INTRAVENOUS | 209360-003 | Dec 23, 2021 | RX | Yes | Yes | 9,867,863 | ⤷ Sign Up | ⤷ Sign Up | ||||
| La Jolla Pharma | GIAPREZA | angiotensin ii acetate | SOLUTION;INTRAVENOUS | 209360-001 | Dec 21, 2017 | RX | Yes | Yes | 10,493,124 | ⤷ Sign Up | ⤷ Sign Up | ||||
| La Jolla Pharma | GIAPREZA | angiotensin ii acetate | SOLUTION;INTRAVENOUS | 209360-003 | Dec 23, 2021 | RX | Yes | Yes | 10,335,451 | ⤷ Sign Up | ⤷ Sign Up | ||||
| La Jolla Pharma | GIAPREZA | angiotensin ii acetate | SOLUTION;INTRAVENOUS | 209360-002 | Dec 21, 2017 | DISCN | Yes | No | 10,335,451 | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
